Nicholas Shorts

Nicholas leads the Pharma column. He is an excellent writer and a team leader with five years’ experience in medical writing. Nicholas is a Journalism degree holder from Texas A&M University. Before taking up Medical literature, he was a Journalism professor. Nicholas is also a poet.

News

Nicholas Shorts August 29, 2019 2:55 AM EDT
0 1,134

FDA Has Fast Track Designation for The Development of Farxiga (Dapagliflozin)

The F.D.A. has awarded Fast Track designation for the development of AstraZeneca – Farxiga (dapagliflozin) to delay the progressions of…
Read More »
News

Nicholas Shorts August 21, 2019 5:29 AM EDT
0 1,139

Astrazeneca Announced Positive Results from The Landmark Part III DAPA-HF Trial

AstraZeneca announced positive results from the landmark Part III DAPA-HF trial which confirmed that Farxiga (dapagliflozin) met the primary composite…
Read More »
News

Nicholas Shorts August 17, 2019 8:01 AM EDT
0 998

FDA Approved Pretomanid Tablets in Combination with Bedaquiline and Linezolid for TB

The US Food and Drug Administration authorized Pretomanid Tablets in combination with bedaquiline and linezolid for the remedy of a…
Read More »
News

Nicholas Shorts August 9, 2019 7:45 AM EDT
0 974

Bayer AG Buys BlueRock Therapeutics to Modify Cell Therapy

Bayer AG and BlueRock Therapeutics declared an agreement under which Bayer will acquire BlueRock Therapeutics, a privately held US-headquartered biotechnology…
Read More »
News

Nicholas Shorts August 7, 2019 4:32 AM EDT
0 880

FDA Approved Turalio Capsules for Treatment of Tenosynovial Giant Cell Tumor

The Food and Drug Administration approved Turalio (pexidartinib) capsules for the treatment of adult sufferers with symptomatic tenosynovial giant cell…
Read More »
News

Nicholas Shorts August 1, 2019 3:30 AM EDT
0 815

Price Tag for A Life Costs – $2.1 Million

When the Food and Drug Administration (FDA) accepted Zolgensma, a lifesaving medication to treat spinal muscular atrophy, parents of younger kids…
Read More »
Pharma

Nicholas Shorts July 24, 2019 7:00 AM EDT
0 779

MVASI™ (bevacizumab-awwb) and KANJINTITM (trastuzumab-anns) Now Available in US

Amgen and Allergan plc proposed that MVASI™ (bevacizumab-awwb), a biosimilar to Avastin® (bevacizumab), and KANJINTITM (trastuzumab-anns), a biosimilar to Herceptin®…
Read More »
News

Nicholas Shorts July 23, 2019 4:40 AM EDT
0 720

FDA Authorized Multiple Applications for First Generics of Lyrica

U.S. Food and Drug Administration authorized multiple applications for first generics of Lyrica (pregabalin) for the management of neuropathic pain…
Read More »
News

Nicholas Shorts July 19, 2019 5:10 AM EDT
0 732

Boehringer Ingelheim to Purchase All Shares of AMAL Therapeutics SA to Concentrate On Novel Cancer Vaccine

Boehringer Ingelheim announced its acquisition of all shares of AMAL Therapeutics SA, a private Swiss biotechnology company concentrate on cancer…
Read More »
News

Nicholas Shorts July 12, 2019 3:12 AM EDT
0 533

Novartis, Amgen, And Banner Alzheimer’s Institute Announced Discontinuation Investigation of The BACE1 Inhibitor CNP520 for Alzheimer’s Prevention

Novartis, Amgen, and Banner Alzheimer’s Institute announced that they would discontinue the investigation of the BACE1 inhibitor CNP520 (umibecestat) in…
Read More »